B-cell linker protein (BLNK)

B-cell linker protein (BLNK) is a cytoplasmic adaptor protein critical for B cell receptor (BCR) signal transduction, acting as a scaffold to assemble signaling complexes downstream of the BCR[1][5]. It coordinates activation of pathways regulating B cell development, proliferation, differentiation, and apoptosis, primarily through interactions with kinases such as SYK, Bruton's tyrosine kinase (Btk), and phospholipase C gamma 2 (PLCG2)[1][2][5]. BLNK is essential for normal B cell maturation, with functional mutations resulting in severe defects in B cell development and various immune-related diseases, including immunodeficiency and B cell malignancies[1][2]. \n\nNotes: \n- There are currently no approved or directly acting drugs that target BLNK itself; therapeutic interest mainly involves modulating the BCR signaling axis or compensating for BLNK deficiency, with kinase inhibitors of BCR pathway components (e.g., BTK inhibitors) used in B cell malignancies[2].\n- BLNK acts as a central signal transducing adaptor, not a receptor, enzyme, or transporter.\n- The most widely used and scientifically accurate full name is \"B-cell linker protein\" (BLNK)[1][5].

Other names

AGM4BASHBLNK-SLY57SLP-65SLP65bcaB-cell linkerB cell linkerB-cell adapter containing a SH2 domain proteinB-cell adaptor containing SH2 domainSrc homology 2 domain-containing leukocyte protein of 65 kDaB-cell activation proteinCytoplasmic adapter protein[1][5]

Drugs theoretically targeting BLNK or its signaling partners would modulate B cell receptor signaling, affect B cell proliferation, differentiation, or survival, and could induce apoptosis in malignant B cells[2].